<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570492</url>
  </required_header>
  <id_info>
    <org_study_id>FFR101782</org_study_id>
    <nct_id>NCT00570492</nct_id>
  </id_info>
  <brief_title>Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize, as accurately as possible, the
      estimation of the difference in pre-pubescent growth velocities between subjects treated
      continuously for one year with FFNS 110mcg QD, the highest dose approved for pediatric use
      in the US, and placebo nasal spray as determined by stadiometry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in the Growth Velocity of Pre-pubescent Pediatric Participants to the End of the 52-week Double-blind (DB) Treatment Period</measure>
    <time_frame>Baseline Period (Weeks -16 to 0) and DB Treatment Period (Weeks 1 to 52)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Height was measured (triplicate measurements) in pre-pubescent pediatric participants via stadiometry at each clinic visit during the entire 76-week study period (16-week Baseline Period, 52-week DB Treatment Period and 8-week Follow-up Period). Growth velocity was calculated by fitting a regression line to all height measurements recorded for the participant during the period and was determined by the slope of the fitted regression line. Change from Baseline was calculated as the value over the 52-week Treatment Period minus the value over the 16-week Baseline Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour Urinary Free Cortisol Excretion</measure>
    <time_frame>Randomization/end of 16-week Baseline Period (Week 0), End of 52-week DB Treatment Period (Week 52), and end of 8-week Follow-up Period (Week 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hypothalamic-pitiutary-adrenal (HPA) axis function was assessed by the measurement of urinary free cortisol, using urine samples collected over the course of 24 hours by the parent/guardian in the participants' home on an out-patient basis within 7 days prior to the indicated time points. Detailed verbal instructions and a take-home instruction card on how to conduct the 24-hour urine collection were provided to the parent/guardian before each collection interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Shifts From Baseline in Nasal Examination (NE) Results</measure>
    <time_frame>Baseline Period (Weeks -16 to 0) and DB Treatment Period (Weeks 1 to 52)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NE included the evaluation of the size of ulcers/polyps (of nasal turbinates/septa) and assessment for mucosal bleeding (MB) at all study visits. Polyps are non-cancerous growths; ulcers are breaks in the skin/mucous membrane with loss of surface tissue, disintegration, and necrosis of epithelial tissue. For MB, Improved=shift from present (&gt;=1 nostril) to absent (both nostrils); Worsened=shift from absent (both nostrils) to present (&gt;=1 nostril). For polyps/ulcers, Improved=shift from large to small or from small to none; Worsened=shift from none to small or from small to none (&gt;=1 nostril).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for the Laboratory Parameters of Alkaline (Alk) Phosphatase (P), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Alk P, ALT, and AST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for the Laboratory Parameters if Albumin and Total Protein</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Albumin and Total Protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for the Laboratory Parameters of Total Bilirubin and Creatinine</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Total Bilirubin and Creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for the Laboratory Parameters of Glucose, Calcium, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Glucose, Calcium, Potassium, Sodium, and Urea/BUN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hematology Values for Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet Counts</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants in the study were evaluated for the following hematology laboratory parameters at the indicated time points: Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Hemoglobin</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hemoglobin was assessed in participants at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Hematocrit</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hematocrit was assessed in participants at indicated the time points. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hematology Values for Red Blood Cells (RBCs)</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>RBCs was assessed in participants at the indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Urine pH</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Urine Specific Gravity</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Urinalysis Results for Urine Bilirubin and Urine Nitrite</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bilirubin is a normal body by-product (bile), and nitrite is a by-product of bacterial growth. Participants were categorized as Negative (Neg.) or Positive (Pos.) based on the absence or presence, respectively, of urine bilirubin (UB) and urine nitrate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Urinalysis Results for Urine Glucose, Urine Ketones, and Urine Proteins</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urine glucose, urine ketones, and urine proteins were measured in participants using a dipstick (qualitative) test at the indicated time points. In this dipstick test, the level of glucose, ketones, and protein in urine samples was recorded as negative (Neg), trace (tr), 1+, 2+, and 3+ (the plus sign increases with a higher level of glucose, ketones, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of glucose, ketones, and proteins in the urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Urinalysis Results for Urine Occult Blood (OB) and the Urine Leukocyte Esterase Test (LET)</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occult blood (OB) is blood that cannot be seen without a microscope. Normal urine does not contain any red blood cells. Leukocyte esterase is an enzyme and is not found in normal urine. In the dipstick (qualitative) test, the level of OB and leukocyte esterase in urine samples was recorded as negative (Neg), small, moderate, large, trace, 1+ (slightly positive), 2+ (positive), and 3+ (high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of OB and urine leukocyte esterase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Urinalysis Results for Urine Appearance (App.)/Clarity and Color</measure>
    <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants were assessed for their urine appearance, which was categorized as clear (normal), cloudy (presence of crystals, blood cells, or bacteria), of turbid. Also, participants were categorized by the color of urine: straw, yellow (normal urine), and dark yellow (DY) (which may be the result of bile in the urine).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone furoate nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone furoate nasal spray</intervention_name>
    <description>Fluticasone furoate nasal spray 110mg QD</description>
    <arm_group_label>Fluticasone furoate nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Placebo nasal spray</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated informed consent obtained from the subject's legal parent/guardian.
             Adequate provisions for assent of children should be provided in accordance with the
             IRB and any local governance.

          -  Age: 5 to less than 7.5 years for females and 5 to less than 8.5 years for males at
             Visit 1.

          -  Subjects must have a diagnosis and history of perennial allergic rhinitis (PAR) as
             follows:

          -  At least a one year clinical history and treatment of PAR (written or verbal
             confirmation from the treating physician) and,

          -  A documented, positive skin test to an appropriate perennial allergen (animal dander,
             house dust mites, cockroaches and/or mold) or documented, historical, in vitro test
             results for a specific IgE (such as RAST, PRIST) within the past 12 months prior to
             Visit 1 will be allowed. A positive skin test during Visit 1 will also be allowed. A
             positive skin test is defined as a wheal 3mm larger than the diluent control for
             prick testing.

        Note: Subjects who meet the above criteria and who may also have seasonal allergic
        rhinitis (SAR) and/or non-allergic rhinitis (NAR) are eligible for randomization.

          -  At Visit 2, the daily rTNSS on any 4 of the last 7 days prior to Visit 2 must be 5.
             Subjects should refrain from using rescue medication during the 7 days prior to Visit
             2.

          -  Pre-pubescence: Tanner Staging equal to 1 for all classifications as assessed by the
             investigator during each of the five baseline study visits (Visit 1 through Visit 5).
             The same investigator should perform this assessment throughout the study for a
             respective subject, if possible, for consistency of assessment. Details are provided
             in the SPM.

          -  Current height measurement via standardized stadiometer is within the 3rd and 97th
             percentile according to the CDC and any local longitudinal standard height charts for
             age and gender as provided in the SPM (Visit 1 through Visit 5).

          -  Body weight and body mass index between the 3rd and 97th percentile according to the
             US CDC standards and any local standards as assessed during each of the five baseline
             study visits (Visit 1 through Visit 5). The US CDC standards are provided in the SPM.

          -  Compliance: Subject's parent/guardian is literate and both subject and
             parent/guardian are deemed capable of complying with all study procedures to include
             proper study drug administration, daily e-diary completion, in-clinic laboratory
             assessments, and in-home 24 hour urine collection during the 76 weeks of study
             participation (Visit 1 through Visit 5).

        Exclusion criteria:

          -  A history or evidence of abnormal growth. Any previous or current condition that
             affects growth, including sleep disorders.

          -  Asthma, with the exception of mild intermittent asthma [National Asthma Education and
             Prevention Program, 2007] (Note: Subjects will be allowed to use short-acting inhaled
             beta2 agonists only on an as needed basis.)

          -  A history of nasal or sinus surgery, septal perforation, or severe obstruction in the
             nose (e.g. nasal polyps).

          -  Any other significant concomitant medical condition. Significant is defined as any
             disease that, in the opinion of the investigator, would put the safety of the subject
             at risk through study participation or which would confound the interpretation of the
             study results if the disease/condition exacerbated during the study. (Visit 1 through
             Visit 5)

          -  Any prior or current use of any medication/treatment that might affect growth
             including, but not limited to, methylphenidate hydrochloride, thyroid hormone, growth
             hormone, anabolic steroids, calcitonin, estrogens, progestins, biphosphonates,
             anticonvulsants or phosphate binding antacids. (Visit 1 through Visit 5).

          -  Use of corticosteroids, defined as:

          -  Inhaled, intranasal, or high potency topical (to include dermatological, optic and
             otic) corticosteroids within 6 weeks prior to Visit 1 or during the baseline period
             (Visit 1 through Visit 5).

          -  Systemic corticosteroids (to include oral and injectable) within 12 weeks prior to
             Visit 1 or during the baseline period (Visit 1 through Visit 5).

          -  Use of other allergy medications within an appropriate timeframe relative to Visit 1
             to allow the medication to be eliminated or no longer producing an effect as well as
             during the baseline period (Visit 1 through Visit 5) including, but not limited to:

          -  Intranasal cromolyn - 14 days

          -  Short-acting prescription and OTC antihistamines - 3 days

          -  Long acting (second-generation) antihistamines (other than the loratadine syrup
             supplied by GSK to treat uncontrolled symptoms of PAR) including fexofenadine,
             cetirizine, desloratadine, and astemizole - 10 days

          -  Long-acting antihistamine: astemizole - 12 weeks

          -  Intranasal antihistamines (e.g. azelastine) -2 weeks

          -  Oral or intranasal decongestants - 3 days

          -  Intranasal, oral or inhaled anticholinergics - 3 days

          -  Oral antileukotrienes - 3 days

          -  Subcutaneous omalizumab - 5 months

          -  Immunotherapy initiated or adjusted within 30 days prior to Visit 1 or during the
             baseline period (Visit 1 through Visit 5) noting that no significant changes in the
             dose, concentration or dilution will be allowed during the study.

          -  Use of immunosuppressive medications 8 weeks prior to screening or during the
             baseline period (Visit 1 through Visit 5) of the study.

          -  Use of any medications that significantly inhibit the cytochrome P450 subfamily
             enzyme CYP3A4, including ritonavir and ketoconazole. (Visit 1 through Visit 5)

          -  Allergy/Intolerance

          -  Known hypersensitivity to corticosteroids or any excipients in the nasal spray

          -  Known hypersensitivity to the antihistamine or decongestant being provided for
             worsening symptoms of rhinitis during the conduct of the study.

          -  Exposure to varicella (Chickenpox) or measles during the 3 weeks prior to screening
             or during the baseline period (Visit 1 through Visit 5), if non-immune. A diagnosis
             of varicella or measles during the baseline period is exclusionary as well.

          -  Recent exposure to an investigational study drug within 30 days prior toVisit 1.

          -  Affiliation with investigational site.

          -  Findings of a clinically significant, abnormal screening (Visit 1) clinical
             laboratory test.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nueve de Julio</city>
        <state>Buenos Aires</state>
        <zip>B6500BWQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaíso</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2007</firstreceived_date>
  <firstreceived_results_date>November 3, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>fluticasone furoate nasal spray</keyword>
  <keyword>growth</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After screening and a 16-week Baseline Period (Pd.), participants (par.) were randomized 1:1 to each treatment arm during the 52-week Treatment Pd. After the Treatment Pd., par. entered an 8-week Follow-up (FU) Pd. during which all par. received placebo nasal spray. Par. completing at least 12 weeks of treatment were to complete the FU Pd.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo: Baseline Period</title>
          <description>Placebo nasal spray administered once daily (OD) as 2 sprays per nostril to all enrolled participants during the 16-week Single-blind Baseline period, to assess the baseline growth velocity</description>
        </group>
        <group group_id="P2">
          <title>Placebo: Double-blind Treatment Period</title>
          <description>Participants were randomized to receive matching placebo nasal spray OD as 2 sprays per nostril during the 52-week Double-blind Treatment Period</description>
        </group>
        <group group_id="P3">
          <title>FFNS 110 Mcg: Double-blind Treatment Period</title>
          <description>Participants were randomized to receive fluticasone furoate nasal spray (FFNS) 110 micrograms (mcg) OD as 2 sprays per nostril during the 52-week Double-blind Treatment Period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>16-week Single-blind Baseline Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="910"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't Meet Inclusion/Exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didn't Meet Randomization Criteria</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Did'nt Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>52-week Double-blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="237"/>
                <participants group_id="P3" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reached Protocol-defined Stop Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
        </group>
        <group group_id="B2">
          <title>FFNS 110 Mcg</title>
          <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="237"/>
                <measurement group_id="B2" value="237"/>
                <measurement group_id="B3" value="474"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics were collected for the Intent-to-Treat (ITT) Population, which included all participants who had been randomized to and received at least one dose of Double-blind study medication.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6.61" spread="0.969"/>
                <measurement group_id="B2" value="6.64" spread="0.933"/>
                <measurement group_id="B3" value="6.63" spread="0.950"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline characteristics were collected for the Intent-to-Treat (ITT) Population, which included all participants who had been randomized to and received at least one dose of Double-blind study medication.</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="148"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="164"/>
                <measurement group_id="B2" value="162"/>
                <measurement group_id="B3" value="326"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Baseline characteristics were collected for the Intent-to-Treat (ITT) Population, which included all participants who had been randomized to and received at least one dose of Double-blind study medication.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African American (Amc)/African Heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Amc Indian or Alaska Native (Alk N)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="189"/>
                <measurement group_id="B2" value="199"/>
                <measurement group_id="B3" value="388"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African Amc/African and Amc Indian or Alk N</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African Amc/African Heritage and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Amc Indian or Alk N and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian/ Other Pacific Islander and White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Growth Velocity of Pre-pubescent Pediatric Participants to the End of the 52-week Double-blind (DB) Treatment Period</title>
        <description>Height was measured (triplicate measurements) in pre-pubescent pediatric participants via stadiometry at each clinic visit during the entire 76-week study period (16-week Baseline Period, 52-week DB Treatment Period and 8-week Follow-up Period). Growth velocity was calculated by fitting a regression line to all height measurements recorded for the participant during the period and was determined by the slope of the fitted regression line. Change from Baseline was calculated as the value over the 52-week Treatment Period minus the value over the 16-week Baseline Period.</description>
        <time_frame>Baseline Period (Weeks -16 to 0) and DB Treatment Period (Weeks 1 to 52)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Growth Population: all randomized participants with height assessments via stadiometry from at least three post-randomization clinic visits during the DB Treatment Period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="218"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Growth Velocity of Pre-pubescent Pediatric Participants to the End of the 52-week Double-blind (DB) Treatment Period</title>
            <description>Height was measured (triplicate measurements) in pre-pubescent pediatric participants via stadiometry at each clinic visit during the entire 76-week study period (16-week Baseline Period, 52-week DB Treatment Period and 8-week Follow-up Period). Growth velocity was calculated by fitting a regression line to all height measurements recorded for the participant during the period and was determined by the slope of the fitted regression line. Change from Baseline was calculated as the value over the 52-week Treatment Period minus the value over the 16-week Baseline Period.</description>
            <units>Centimeters per year (cm/year)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.46" spread="0.10"/>
                  <measurement group_id="O2" value="5.19" spread="0.10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.270</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>An analysis of covariance (ANCOVA) was performed to estimate the mean treatment difference in growth velocity over the treatment period, adjusting for baseline growth velocity, age, gender, and country.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-hour Urinary Free Cortisol Excretion</title>
        <description>Hypothalamic-pitiutary-adrenal (HPA) axis function was assessed by the measurement of urinary free cortisol, using urine samples collected over the course of 24 hours by the parent/guardian in the participants' home on an out-patient basis within 7 days prior to the indicated time points. Detailed verbal instructions and a take-home instruction card on how to conduct the 24-hour urine collection were provided to the parent/guardian before each collection interval.</description>
        <time_frame>Randomization/end of 16-week Baseline Period (Week 0), End of 52-week DB Treatment Period (Week 52), and end of 8-week Follow-up Period (Week 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Urine Cortisol Population: all randomized participants excluding those whose urine samples were considered to have confounding factors affecting the interpretation of the 24-hour urinary cortisol results. One participant in each arm had a Baseline value &lt;1.0 and was not analyzed. Some participants had samples that were not acceptable for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="172"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean 24-hour Urinary Free Cortisol Excretion</title>
            <description>Hypothalamic-pitiutary-adrenal (HPA) axis function was assessed by the measurement of urinary free cortisol, using urine samples collected over the course of 24 hours by the parent/guardian in the participants' home on an out-patient basis within 7 days prior to the indicated time points. Detailed verbal instructions and a take-home instruction card on how to conduct the 24-hour urine collection were provided to the parent/guardian before each collection interval.</description>
            <units>Micrograms per 24 hours (mcg/24 hours)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>End of 16-week Baseline Period, n=168, 172</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.771" spread="6.0479"/>
                  <measurement group_id="O2" value="9.242" spread="5.5821"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End of 52-week DB Treatment Period, n=163, 169</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.340" spread="9.6775"/>
                  <measurement group_id="O2" value="11.125" spread="9.2195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End of 8-week Follow-up Period, n=161, 167</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.615" spread="6.6903"/>
                  <measurement group_id="O2" value="10.311" spread="5.9986"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Shifts From Baseline in Nasal Examination (NE) Results</title>
        <description>NE included the evaluation of the size of ulcers/polyps (of nasal turbinates/septa) and assessment for mucosal bleeding (MB) at all study visits. Polyps are non-cancerous growths; ulcers are breaks in the skin/mucous membrane with loss of surface tissue, disintegration, and necrosis of epithelial tissue. For MB, Improved=shift from present (&gt;=1 nostril) to absent (both nostrils); Worsened=shift from absent (both nostrils) to present (&gt;=1 nostril). For polyps/ulcers, Improved=shift from large to small or from small to none; Worsened=shift from none to small or from small to none (&gt;=1 nostril).</description>
        <time_frame>Baseline Period (Weeks -16 to 0) and DB Treatment Period (Weeks 1 to 52)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-Treat (ITT) Population: all participants who had been randomized to and received at least one dose of double-blind study medication. Most participants received examinations at each visit; however, on some occasions, some assessments were not completed for various reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="191"/>
                  <measurement group_id="O2" value="188"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Shifts From Baseline in Nasal Examination (NE) Results</title>
            <description>NE included the evaluation of the size of ulcers/polyps (of nasal turbinates/septa) and assessment for mucosal bleeding (MB) at all study visits. Polyps are non-cancerous growths; ulcers are breaks in the skin/mucous membrane with loss of surface tissue, disintegration, and necrosis of epithelial tissue. For MB, Improved=shift from present (&gt;=1 nostril) to absent (both nostrils); Worsened=shift from absent (both nostrils) to present (&gt;=1 nostril). For polyps/ulcers, Improved=shift from large to small or from small to none; Worsened=shift from none to small or from small to none (&gt;=1 nostril).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mucosal Bleeding, Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mucosal Bleeding, No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mucosal Bleeding, Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ulcers, Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ulcers, No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="191"/>
                  <measurement group_id="O2" value="188"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ulcers, Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polyps, Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polyps, No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="188"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polyps, Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for the Laboratory Parameters of Alkaline (Alk) Phosphatase (P), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)</title>
        <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Alk P, ALT, and AST.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for the Laboratory Parameters of Alkaline (Alk) Phosphatase (P), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)</title>
            <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Alk P, ALT, and AST.</description>
            <units>International Units per liter (IU/L)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Alk P, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="246.8" spread="57.45"/>
                  <measurement group_id="O2" value="249.8" spread="67.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alk P, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="261.9" spread="61.96"/>
                  <measurement group_id="O2" value="262.9" spread="71.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alk P, Follow-up Period, n=175, 174</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="264.2" spread="59.67"/>
                  <measurement group_id="O2" value="264.6" spread="67.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.8" spread="4.54"/>
                  <measurement group_id="O2" value="15.1" spread="4.73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.9" spread="8.50"/>
                  <measurement group_id="O2" value="15.8" spread="5.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, Follow-up Period, n=175, 174</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.7" spread="14.41"/>
                  <measurement group_id="O2" value="17.2" spread="13.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, Baseline Period, n=229, 232</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.4" spread="4.89"/>
                  <measurement group_id="O2" value="28.1" spread="4.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, DB Treatment Period, n=175, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.0" spread="5.49"/>
                  <measurement group_id="O2" value="27.6" spread="4.87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST, Follow-up Period, n=169, 174</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.7" spread="8.93"/>
                  <measurement group_id="O2" value="28.3" spread="10.44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for the Laboratory Parameters if Albumin and Total Protein</title>
        <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Albumin and Total Protein.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for the Laboratory Parameters if Albumin and Total Protein</title>
            <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Albumin and Total Protein.</description>
            <units>Grams per liter (g/L)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Albumin, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.8" spread="2.29"/>
                  <measurement group_id="O2" value="46.0" spread="2.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.7" spread="2.24"/>
                  <measurement group_id="O2" value="45.9" spread="2.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.8" spread="2.31"/>
                  <measurement group_id="O2" value="45.6" spread="2.36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72.0" spread="3.78"/>
                  <measurement group_id="O2" value="71.9" spread="4.30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71.7" spread="3.76"/>
                  <measurement group_id="O2" value="71.7" spread="3.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Protein, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71.5" spread="3.66"/>
                  <measurement group_id="O2" value="71.5" spread="3.83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for the Laboratory Parameters of Total Bilirubin and Creatinine</title>
        <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Total Bilirubin and Creatinine.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for the Laboratory Parameters of Total Bilirubin and Creatinine</title>
            <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Total Bilirubin and Creatinine.</description>
            <units>Micromoles (µmol)/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Total Bilirubin, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.9" spread="2.43"/>
                  <measurement group_id="O2" value="7.2" spread="3.40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2" spread="2.69"/>
                  <measurement group_id="O2" value="7.7" spread="3.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" spread="2.72"/>
                  <measurement group_id="O2" value="7.1" spread="3.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.3" spread="7.98"/>
                  <measurement group_id="O2" value="43.6" spread="7.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.0" spread="8.34"/>
                  <measurement group_id="O2" value="44.6" spread="8.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44.5" spread="7.38"/>
                  <measurement group_id="O2" value="45.0" spread="7.72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for the Laboratory Parameters of Glucose, Calcium, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN)</title>
        <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Glucose, Calcium, Potassium, Sodium, and Urea/BUN.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for the Laboratory Parameters of Glucose, Calcium, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN)</title>
            <description>Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: Glucose, Calcium, Potassium, Sodium, and Urea/BUN.</description>
            <units>Millimoles (mmol)/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Glucose, Baseline Period, n=230, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.83" spread="0.683"/>
                  <measurement group_id="O2" value="4.86" spread="0.690"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.82" spread="0.782"/>
                  <measurement group_id="O2" value="4.78" spread="0.720"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.87" spread="0.840"/>
                  <measurement group_id="O2" value="4.85" spread="0.700"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium, Baseline Period, n=229, 232</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.441" spread="0.0786"/>
                  <measurement group_id="O2" value="2.435" spread="0.0993"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium, DB Treatment Period, n=175, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.437" spread="0.0776"/>
                  <measurement group_id="O2" value="2.440" spread="0.0847"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium, Follow-up Period, n=169, 173</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.438" spread="0.0769"/>
                  <measurement group_id="O2" value="2.436" spread="0.0820"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium, Baseline Period, n=229, 232</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.30" spread="0.404"/>
                  <measurement group_id="O2" value="4.31" spread="0.437"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium, DB Treatment Period, n=175, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.30" spread="0.373"/>
                  <measurement group_id="O2" value="4.30" spread="0.345"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium, Follow-up Period, n=169, 173</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.28" spread="0.362"/>
                  <measurement group_id="O2" value="4.32" spread="0.409"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium, Baseline Period, n=231, 234</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139.4" spread="1.90"/>
                  <measurement group_id="O2" value="139.3" spread="1.83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139.1" spread="1.65"/>
                  <measurement group_id="O2" value="139.2" spread="1.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139.3" spread="1.89"/>
                  <measurement group_id="O2" value="139.4" spread="2.19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urea/BUN, Baseline Period, n=231, 235</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.99" spread="1.897"/>
                  <measurement group_id="O2" value="4.77" spread="1.195"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urea/BUN, DB Treatment Period, n=184, 182</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.82" spread="1.315"/>
                  <measurement group_id="O2" value="4.82" spread="1.294"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urea/BUN, Follow-up Period, n=175, 175</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.93" spread="1.219"/>
                  <measurement group_id="O2" value="4.75" spread="1.274"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hematology Values for Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet Counts</title>
        <description>Participants in the study were evaluated for the following hematology laboratory parameters at the indicated time points: Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet counts.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="228"/>
                  <measurement group_id="O2" value="231"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Hematology Values for Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet Counts</title>
            <description>Participants in the study were evaluated for the following hematology laboratory parameters at the indicated time points: Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet counts.</description>
            <units>Giga (10^9) cells (Gi)/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Basophil, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.026" spread="0.0176"/>
                  <measurement group_id="O2" value="0.025" spread="0.0151"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Basophil, DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.026" spread="0.0198"/>
                  <measurement group_id="O2" value="0.027" spread="0.0184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Basophil, Follow-up Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.026" spread="0.0172"/>
                  <measurement group_id="O2" value="0.025" spread="0.0165"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eosinophil, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.395" spread="0.3292"/>
                  <measurement group_id="O2" value="0.455" spread="0.3859"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eosinophil, DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.442" spread="0.3505"/>
                  <measurement group_id="O2" value="0.394" spread="0.3577"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eosinophil, Follow-up Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.419" spread="0.3337"/>
                  <measurement group_id="O2" value="0.409" spread="0.3296"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocyte, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.046" spread="0.9686"/>
                  <measurement group_id="O2" value="2.987" spread="0.9158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocyte, DB Treatment Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.779" spread="0.8038"/>
                  <measurement group_id="O2" value="2.820" spread="0.8424"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocyte, Follow-up Period, n=169, 173</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.871" spread="0.8784"/>
                  <measurement group_id="O2" value="2.841" spread="0.8107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.71" spread="2.077"/>
                  <measurement group_id="O2" value="7.36" spread="1.818"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.14" spread="1.899"/>
                  <measurement group_id="O2" value="6.98" spread="1.896"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, Follow-up Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.18" spread="1.945"/>
                  <measurement group_id="O2" value="6.96" spread="1.894"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocyte, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.348" spread="0.1655"/>
                  <measurement group_id="O2" value="0.373" spread="0.1870"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocyte, DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.320" spread="0.1393"/>
                  <measurement group_id="O2" value="0.343" spread="0.1598"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocyte, Follow-up Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.334" spread="0.1471"/>
                  <measurement group_id="O2" value="0.326" spread="0.1592"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Segmented Neu, Baseline Period, n=228, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.892" spread="1.6722"/>
                  <measurement group_id="O2" value="3.517" spread="1.5347"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Segmented Neu, DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.572" spread="1.5407"/>
                  <measurement group_id="O2" value="3.391" spread="1.4828"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Segmented Neu, Follow-up Period, n=177, 179</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.572" spread="1.5623"/>
                  <measurement group_id="O2" value="3.354" spread="1.4379"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet, Baseline Period, n=230, 230</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="313.8" spread="70.19"/>
                  <measurement group_id="O2" value="314.1" spread="59.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet, DB Treatment Period, n=187, 187</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="278.6" spread="55.58"/>
                  <measurement group_id="O2" value="279.5" spread="49.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet, Follow-up Period, n=175, 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="276.4" spread="49.27"/>
                  <measurement group_id="O2" value="283.6" spread="59.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Hemoglobin</title>
        <description>Hemoglobin was assessed in participants at the indicated time points.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="231"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for Hemoglobin</title>
            <description>Hemoglobin was assessed in participants at the indicated time points.</description>
            <units>g/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period, n=231, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129.5" spread="7.87"/>
                  <measurement group_id="O2" value="128.4" spread="8.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="131.8" spread="7.32"/>
                  <measurement group_id="O2" value="130.8" spread="7.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Period, n=177, 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="132.1" spread="7.43"/>
                  <measurement group_id="O2" value="130.0" spread="7.90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Hematocrit</title>
        <description>Hematocrit was assessed in participants at indicated the time points. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs).</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="231"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for Hematocrit</title>
            <description>Hematocrit was assessed in participants at indicated the time points. Hematocrit is the percentage of blood volume (BV) that is occupied by red blood cells (RBCs).</description>
            <units>Percentage of BV occupied by RBCs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period, n=231, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3823" spread="0.02296"/>
                  <measurement group_id="O2" value="0.3783" spread="0.02480"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3904" spread="0.02291"/>
                  <measurement group_id="O2" value="0.3873" spread="0.02481"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Period, n=177, 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3906" spread="0.02227"/>
                  <measurement group_id="O2" value="0.3844" spread="0.02416"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hematology Values for Red Blood Cells (RBCs)</title>
        <description>RBCs was assessed in participants at the indicated time points.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="231"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Hematology Values for Red Blood Cells (RBCs)</title>
            <description>RBCs was assessed in participants at the indicated time points.</description>
            <units>Trillion (10^12) cells (Ti)/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period, n=231, 231</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.59" spread="0.312"/>
                  <measurement group_id="O2" value="4.54" spread="0.327"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DB Treatment Period, n=186, 188</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.56" spread="0.303"/>
                  <measurement group_id="O2" value="4.53" spread="0.319"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Period, n=177, 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.57" spread="0.306"/>
                  <measurement group_id="O2" value="4.50" spread="0.314"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Urine pH</title>
        <description>Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for Urine pH</title>
            <description>Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.02" spread="0.477"/>
                  <measurement group_id="O2" value="6.00" spread="0.536"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.02" spread="0.547"/>
                  <measurement group_id="O2" value="6.05" spread="0.507"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.05" spread="0.538"/>
                  <measurement group_id="O2" value="6.05" spread="0.524"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Urine Specific Gravity</title>
        <description>Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Values for Urine Specific Gravity</title>
            <description>Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0240" spread="0.00718"/>
                  <measurement group_id="O2" value="1.0234" spread="0.00673"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0244" spread="0.00695"/>
                  <measurement group_id="O2" value="1.0234" spread="0.00649"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0237" spread="0.00642"/>
                  <measurement group_id="O2" value="1.0242" spread="0.00672"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Urinalysis Results for Urine Bilirubin and Urine Nitrite</title>
        <description>Bilirubin is a normal body by-product (bile), and nitrite is a by-product of bacterial growth. Participants were categorized as Negative (Neg.) or Positive (Pos.) based on the absence or presence, respectively, of urine bilirubin (UB) and urine nitrate.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Urinalysis Results for Urine Bilirubin and Urine Nitrite</title>
            <description>Bilirubin is a normal body by-product (bile), and nitrite is a by-product of bacterial growth. Participants were categorized as Negative (Neg.) or Positive (Pos.) based on the absence or presence, respectively, of urine bilirubin (UB) and urine nitrate.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>UB-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UB-Pos, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UB-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="182"/>
                  <measurement group_id="O2" value="181"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UB-Pos, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UB-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="186"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>UB-Pos, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                  <measurement group_id="O2" value="228"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Pos, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="178"/>
                  <measurement group_id="O2" value="176"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Pos, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="183"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Nitrite-Pos, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Urinalysis Results for Urine Glucose, Urine Ketones, and Urine Proteins</title>
        <description>Urine glucose, urine ketones, and urine proteins were measured in participants using a dipstick (qualitative) test at the indicated time points. In this dipstick test, the level of glucose, ketones, and protein in urine samples was recorded as negative (Neg), trace (tr), 1+, 2+, and 3+ (the plus sign increases with a higher level of glucose, ketones, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of glucose, ketones, and proteins in the urine.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Urinalysis Results for Urine Glucose, Urine Ketones, and Urine Proteins</title>
            <description>Urine glucose, urine ketones, and urine proteins were measured in participants using a dipstick (qualitative) test at the indicated time points. In this dipstick test, the level of glucose, ketones, and protein in urine samples was recorded as negative (Neg), trace (tr), 1+, 2+, and 3+ (the plus sign increases with a higher level of glucose, ketones, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of glucose, ketones, and proteins in the urine.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Urine Glucose-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                  <measurement group_id="O2" value="181"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose-Tr, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="186"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Glucose-1+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Trace, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-1+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                  <measurement group_id="O2" value="176"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Tr, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-Trace, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-1+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="218"/>
                  <measurement group_id="O2" value="207"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Trace, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-1+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-2+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Tr, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-1+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-2+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-Trace, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Protein-1+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-2+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Ketones-3+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Urinalysis Results for Urine Occult Blood (OB) and the Urine Leukocyte Esterase Test (LET)</title>
        <description>Occult blood (OB) is blood that cannot be seen without a microscope. Normal urine does not contain any red blood cells. Leukocyte esterase is an enzyme and is not found in normal urine. In the dipstick (qualitative) test, the level of OB and leukocyte esterase in urine samples was recorded as negative (Neg), small, moderate, large, trace, 1+ (slightly positive), 2+ (positive), and 3+ (high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of OB and urine leukocyte esterase.</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Urinalysis Results for Urine Occult Blood (OB) and the Urine Leukocyte Esterase Test (LET)</title>
            <description>Occult blood (OB) is blood that cannot be seen without a microscope. Normal urine does not contain any red blood cells. Leukocyte esterase is an enzyme and is not found in normal urine. In the dipstick (qualitative) test, the level of OB and leukocyte esterase in urine samples was recorded as negative (Neg), small, moderate, large, trace, 1+ (slightly positive), 2+ (positive), and 3+ (high positive). Participants were categorized as negative or positive based on the absence or presence, respectively, of OB and urine leukocyte esterase.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Urine OB-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="226"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Small, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Moderate, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Trace, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-1+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="178"/>
                  <measurement group_id="O2" value="178"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Trace, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-1+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-3+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-Trace, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-1+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine OB-2+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Neg, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="220"/>
                  <measurement group_id="O2" value="219"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Small, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Moderate, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Large, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Trace, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-1+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-2+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-3+, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Neg, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="170"/>
                  <measurement group_id="O2" value="163"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Trace, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-1+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-2+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-3+, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Neg, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-Trace, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-1+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-2+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine LET-3+, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Urinalysis Results for Urine Appearance (App.)/Clarity and Color</title>
        <description>Participants were assessed for their urine appearance, which was categorized as clear (normal), cloudy (presence of crystals, blood cells, or bacteria), of turbid. Also, participants were categorized by the color of urine: straw, yellow (normal urine), and dark yellow (DY) (which may be the result of bile in the urine).</description>
        <time_frame>Baseline Period (Weeks -16 to 0), DB Treatment Period (Weeks 1 to 52), and Follow-up Period (Weeks 53 to 60)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>ITT Population. Only those participants remaining in the study and contributing viable samples at the various time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg</title>
            <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Urinalysis Results for Urine Appearance (App.)/Clarity and Color</title>
            <description>Participants were assessed for their urine appearance, which was categorized as clear (normal), cloudy (presence of crystals, blood cells, or bacteria), of turbid. Also, participants were categorized by the color of urine: straw, yellow (normal urine), and dark yellow (DY) (which may be the result of bile in the urine).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Urine App.-Clear, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Cloudy, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Turbid, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Clear, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="139"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Cloudy, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Turbid, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Clear, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139"/>
                  <measurement group_id="O2" value="137"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Cloudy, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine App.-Turbid, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Straw, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Yellow, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="214"/>
                  <measurement group_id="O2" value="213"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-DY, Baseline Period, n=233, 229</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Straw, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Yellow, DB Treatment Period, n=182,181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-DY, DB Treatment Period, n=182, 181</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Straw, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-Yellow, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="160"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine Color-DY, Follow-up Period, n=180, 186</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, in the following 52-week Double-blind Treatment Period (after randomization), and then in the 8-week Single-blind Follow-up Period.</description>
        </group>
        <group group_id="E2">
          <title>FFNS 110 Mcg</title>
          <description>Participants received placebo nasal spray OD (as 2 sprays per nostril at each time point) in the 16-week Single-blind Baseline Period, and then received FFNS 110 mcg OD in the following 52-week Double-blind Treatment Period. Participants again received placebo nasal spray OD in the 8-week Single-blind Follow-up Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia Primary Atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
